ALA-101: CAR19-iNKT

ALA-101 is a next-generation "off-the-shelf" CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias. 

Archery target with three arrows hitting the bullseye

What is ALA-101’s targeting mechanism?

ALA-101 contains a CAR that targets CD19. CD19 is an antigen found on the surface of many blood cancers. Certain forms of lymphoma also express CD1d, which when bound to a glycolipid, can be recognised by iNKT cells, making them dual targeting.   

Outline of a clipboard with a document featuring a profile icon, lines of text, and a medical cross symbol.

What diseases will ALA-101 treat?

ALA-101 is being developed to target CD19+ lymphoma and leukemia. There were more than 140,000 cases of CD19+ lymphomas and leukaemias in the US alone in 2023 which led to more than 40,000 deaths.

Blue question mark icon.

How could this change the cancer landscape?  

Unlike the currently approved CAR-T products that treat CD19+ haematological malignancies, which must be manufactured from the patients T cells, ALA-101 is being developed as an off-the-shelf product. This could be transformative for the sector.

Diagram illustrating immune response to cancer, showing CAR-iNKT cell targeting a cancer cell, recruiting T cells and NK cells, and blocking TAM and MDSC cells.

Learn more about our iNKT cell technology and grasp its future potential in the fight against cancer.